The restoration of BMAL1 oscillation in CML patients following Sirt1 inhibition suggests Sirt1 may be a feasible drug target to restore core clock oscillation in CML patients as part of a chronotherapy strategy for treating CML. The gene discussed is CLOCK; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.